miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I

被引:49
|
作者
Song, Bin [1 ]
Ji, Weiping [1 ]
Gu, Shiwei [1 ]
Liu, Anan [1 ]
Jing, Wei [1 ]
Shao, Chenghao [1 ]
Li, Gang [1 ]
Jin, Gang [1 ]
机构
[1] Second Mil Med Univ, Dept Pancreat Surg, Changhai Hosp, Shanghai 200082, Peoples R China
基金
上海市自然科学基金;
关键词
miR-545; Pancreatic ductal adenocarcinoma; RIG-I; Patients survival; Cancer growth; HEPATOCELLULAR-CARCINOMA; MICRORNAS; CANCER; RECOGNITION; SURVIVAL; RNA; ACTIVATION; APOPTOSIS; GENES; CELLS;
D O I
10.1016/j.febslet.2014.10.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) ranks fourth on the list of cancer-related causes of death. Deregulation or dysfunction of miRNAs contribute to cancer development. In this study, we found that low miR-545 level and high RIG-I protein in PDAC tissues were both correlated with low survival rate. MiR-545 up-regulation inhibited PDAC cell lines growth and vice versa. 3'UTR of RIG-I was targeted by miR-545. Thus we concluded that low miR-545 levels in PDAC promote tumor cells growth, and this is associated with reduced survival in PDAC patients. MiR-545 exerts its effects by directly targeting RIG-1. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:4375 / 4381
页数:7
相关论文
共 50 条
  • [41] Interplay of miR-21 and FoxO1 modulates growth of pancreatic ductal adenocarcinoma
    Song, Weifeng
    Wang, Lei
    Wang, Liwei
    Li, Qi
    TUMOR BIOLOGY, 2015, 36 (06) : 4741 - 4745
  • [42] Hepatitis E Virus Methyltransferase Inhibits Type I Interferon Induction by Targeting RIG-I
    Kang, Sangmin
    Choi, Changsun
    Choi, Insoo
    Han, Kwi-Nam
    Roh, Seong Woon
    Choi, Jongsun
    Kwon, Joseph
    Park, Mi-Kyung
    Kim, Seong-Jun
    Myoung, Jinjong
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2018, 28 (09) : 1554 - 1562
  • [43] Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma
    Budka, Justyna
    Debowski, Dawid
    Mai, Shaoshan
    Narajczyk, Magdalena
    Hac, Stanislaw
    Rolka, Krzysztof
    Vrettos, Eirinaios I.
    Tzakos, Andreas G.
    Inkielewicz-Stepniak, Iwona
    PHARMACEUTICS, 2024, 16 (02)
  • [44] A novel hedgehog signaling inhibitor for targeting pancreatic ductal adenocarcinoma
    Khire, Atul
    Zhong, Yi
    Rajanala, Kalpana
    Iacobuzio-Donahue, Christine
    Resh, Marilyn D.
    CANCER RESEARCH, 2019, 79 (13)
  • [45] Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises
    Mei, Lin
    Du, Wei
    Ma, Wen Wee
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (03) : 487 - 494
  • [46] Targeting importin-YAP axis in pancreatic ductal adenocarcinoma
    Zeng, Renya
    Dong, Jixin
    CANCER RESEARCH, 2022, 82 (12)
  • [47] The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
    Wu, Yang
    Zhang, Chun
    Jiang, Kuirong
    Werner, Jens
    Bazhin, Alexandr V.
    D'Haese, Jan G.
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [48] Targeting LDLR-overexpressing glioblastoma and pancreatic ductal adenocarcinoma
    Tworowska, Izabela
    Flores, Leo, II
    Qu, Xuewei
    Malicet, Cedric
    Lecorche, Pascaline
    Temsamani, Jamal
    Delpassand, Ebrahim
    NUCLEAR MEDICINE AND BIOLOGY, 2022, 108 : S217 - S218
  • [49] A rat model of pancreatic ductal adenocarcinoma: Targeting chemical carcinogens
    Rivera, JA
    GraemeCook, F
    Werner, J
    Zgraggen, K
    Rustgi, AK
    Rattner, DW
    Warshaw, AL
    FernandezdelCastillo, C
    SURGERY, 1997, 122 (01) : 82 - 90
  • [50] Peptides as a targeting strategy to eradicate Pancreatic Ductal Adenocarcinoma (PDAC)
    Parrasia, Sofia
    Rossa, Andrea
    Bachmann, Magdalena
    Corbo, Vincenzo
    Mattarei, Andrea
    Ruzza, Paolo
    Biasutto, Lucia
    Szabo, Ildiko
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2024, 1870 (08): : 10 - 10